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Background: Allergy immunotherapy is an effective treatment for patients with allergic rhinitis whose symptoms
are unresolved with pharmacotherapy. Allergy immunotherapy for grass pollen-induced allergic rhinitis is available
in three modalities: subcutaneous immunotherapy and sublingual immunotherapy as a tablet or drop. This study
aimed to understand trends in allergy immunotherapy prescribing and practice patterns for grass allergies in adult
and paediatric patients in Germany.
Methods: A retrospective cohort study was conducted using IMS Disease Analyzer in Germany. Patients with an
allergy immunotherapy prescription for grass pollen (Anatomical Therapeutic Chemical [ATC] classification code
V01AA02) from September 2005 to December 2012 were included in the study. General Practitioners (GPs),
dermatologists, Ear, Nose and Throat (ENT)-specialists, paediatricians and pneumologists were included as the
allergy immunotherapy prescribing physicians in the study. Descriptive analyses were conducted on patient
characteristics at index and prescribing physician specialty; a test for trend was conducted for timing of initiation of
first allergy immunotherapy prescription in each annual prescribing season.
Results: Eighteen thousand eight hundred fifty eligible patients were identified during the study period. The
majority of patients received subcutaneous immunotherapy; however, the proportion of patients receiving
sublingual immunotherapy tablets increased from 8 % in 2006/2007 to 29 % in 2011/2012 (p < 0.001). Initiation of
subcutaneous immunotherapy and Oralair® generally peaked during each prescribing year in two seasons
(September-October and January) while GRAZAX® prescriptions peaked in autumn (September-October).
ENT-specialists and dermatologists were the largest allergy immunotherapy prescribers in adults, while paediatricians
and ENT-specialists were the largest prescribers of allergy immunotherapy in paediatric patients.
Conclusions: Subcutaneous immunotherapy remained the dominant allergy immunotherapy modality for grass
pollen-induced allergic rhinitis in Germany for adult and paediatric patients; however, there was a marked increase in
proportion of patients receiving sublingual immunotherapy tablets from 2006/2007 to 2011/2012, after their introduction
to the market in 2006. ENT-specialists, dermatologists and paediatricians were responsible for the majority of prescribing.
The predominance of particular modalities within certain physician specialties likely reflects different treatment goals or
needs.
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Allergic rhinitis (AR) affects 23 % of the population in
Western Europe, with approximately half affected by
grass pollen-induced rhinitis [1]. Allergy Immunotherapy
(AIT) desensitizes the immune system to allergens (in-
cluding grass pollen) and is a treatment option to alleviate
AR symptoms when a patient is not adequately managed
with symptomatic medication. The benefits of AIT can in-
clude symptom reduction, reduced need for symptom re-
lieving medications, disease modification, improvement in
asthma symptoms, and prevention of new sensitizations
and allergic asthma [2–13]. AIT is available in three mo-
dalities: subcutaneous immunotherapy (SCIT) and sublin-
gual immunotherapy (SLIT) in both a tablet (SLIT-tablet)
and drop (SLIT-drop) formulation. SLIT-tablet is a rela-
tively new modality, with two products (GRAZAX®: stan-
dardized allergen extract of grass pollen from Phleum
pratense 75,000 Standardized Quality units Tablet per
oral lyophilisate; and Oralair®: 5-grass pollen allergen
extract tablet, 100 index of reactivity [IR] & 300 IR) avail-
able in European countries since 2006 and 2008, respect-
ively [14, 15].
AIT is effective and well tolerated in adults and chil-
dren, and the Joint Task Force on Practice Parameters
recommends that AIT can be considered for patients
who have demonstrable evidence of specific immuno-
globulin E antibodies to clinically relevant allergens [16].
Although the comparative efficacy of SCIT and SLIT has
not been established with direct comparative random-
ized controlled trials, the clinical efficacy of SLIT (irre-
spective of allergen) has been suggested to be similar to
SCIT based on select open, controlled trials in an evi-
dence review [17]; however, a review of meta-analyses
has suggested greater efficacy of SCIT [18], while other
studies have found no statistically significant difference
between modalities [19].
In practice, choice of modality is likely based on pa-
tient and prescriber preferences. SCIT allows more time
for patient-physician interaction as it is physician-
administered and can treat multiple allergens at once;
however, the treatment regimen is lengthy (generally 3–
5 years), the frequency of visits may be inconvenient,
and the modality unattractive to patients with needle
phobia [20]. Although speculative, given that SLIT-
tablets have not been available in the United States (US)
until recently, SCIT may be found to be preferred amongst
allergists in the US as these physicians typically formulate
extracts themselves; whereas in Europe virtually all AIT is
formulated by extract manufacturers [21].
The three AIT modalities (SCIT, SLIT-drops, SLIT-
tablets) have been available for several years in Germany,
with treatment initiated by a range of physician specialties,
some with sub-specialty in allergology. In the present
study we describe the AIT prescribing and practicepatterns for paediatric and adult grass pollen-induced AR
patients in Germany. The study covers the period pre-
and post-introduction of SLIT tablets, thus enabling the
study of the impact of this new modality on prescribing
patterns.
Methods
Study design and data source
This was a retrospective cohort study using the IMS
Disease Analyzer (DA) database in Germany. DA col-
lects data from Electronic Medical Records of General
Practitioners (GP) and office-based specialists and has
been shown to be representative of the German popula-
tion [22]. GPs, dermatologists, Ear, Nose and Throat
(ENT)-specialists, paediatricians, and pneumologists were
included in this study. Dermatologists were included
based on their history as the original allergists in Germany
and paediatricians based on the frequency of allergology
training in this specialty. Allergology is a sub-specialty in
Germany, rather than a distinct specialty (e.g., paediatri-
cians can have sub-specialty in allergology); this is in con-
trast to some countries where allergology is a distinct
specialty (e.g., US).
Patient inclusion criteria
Patients were included in the study if they received an
AIT prescription with an Anatomical Therapeutic Chem-
ical (ATC) classification code for grass pollen (V01AA02)
during the study period. Patients were excluded if they
had multiple AIT modalities prescribed at index or had a
record of an insect allergy (ATC V01AA07), since insect
venom AIT regimens differ from that of seasonal allergies.
There were no criteria for inclusion or exclusion of pa-
tients receiving multi-allergen immunotherapy.
Analyses
To meet the study objectives, two specific analyses were
conducted. The first was a cross-sectional analysis to de-
termine temporal trends of AIT during each “prescribing
year” (1 September – 31 August annually) from 2005 to
2012. The prescribing year was designated to begin in
September based on clinical input regarding customary
approach to AIT initiation in Germany, as prescriptions
started in September are intended to alleviate symptoms
in the upcoming season (co-author: U. Wahn). The same
patient could have been included in analyses across
years, but only their first prescription each year was in-
cluded in annual analyses. Patients were grouped by mo-
dality with SLIT-tablets segmented into GRAZAX® and
Oralair®.
McNemar’s test of difference between first and last
year of the study period and Chi-squared test for trend
over time were used to determine statistical significance
of differences in proportion of patients prescribed each
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tions were compared within each year to observe differ-
ences in trend that may have arisen from specification of
the prescribing year.
A second analysis was undertaken to examine patient
characteristics and physician specialities related to AIT.
The first AIT prescription identified for a patient be-
tween September 1st 2005 and December 31st 2012 was
considered the index prescription. Medical records prior
to index were searched for prior AIT use. Information
on the physician associated with the index prescription
determined physician specialty. The proportion of pa-
tients prescribed each modality by physician type and
age group was calculated over the entire study period
and in the calendar year of 2012 alone representing the
most recent year. Descriptive statistics for number of
AIT patients treated by each prescribing physician were
also calculated.
Patients were characterized at index by age, gender,
co-morbidities, history of grass pollen AIT use, and in-
surance status. Paediatric patients were <18 years of age
at index. A diagnosis code of a relevant co-morbidity
(asthma, sinusitis, atopic dermatitis, conjunctivitis, urti-
caria, other documented allergies [via ATC code]) orTable 1 Patient characteristics at allergy immunotherapy initiation
Characteristic All patients (n = 18,850)
Agea 26.7 ± 14.35 (24.0)
SLIT-tablets 28.5 ± 14.76 (27.0)
SLIT-drop 26.5 ± 15.44 (25.0)
SCIT 26.2 ± 14.09 (24.0)





State (public) 16,502 (88 %)
Private 2348 (12 %)
Prior AIT usage at index 957 (5 %)
SLIT-tablets 31 (1 %)
SLIT-drop 35 (4 %)
SCIT 891 (7 %)
Co-morbiditiesb
Asthma 7904 (42 %)
Conjunctivitis 4215 (22 %)
Atopic Dermatitis 3770 (20 %)
Sinusitis 2954 (16 %)
Concomitant ARC usagec 13,403 (71 %)
aMean ± SD (median)
bCo-morbidities not mutually exclusive
cAt index or post-indexprescription of an asthma or atopic dermatitis medica-
tion pre-index were used to determine co-morbidities.
Patients were classified as publicly or privately insured.
Prescriptions of concomitant allergic rhinoconjunctivitis
(ARC) medication were based on record of a prescrip-
tion one month pre-index or during the entire post-
index period. The length of the post-index period varied
between patients and ended when a patient no longer
attended a physician in DA or on December 31, 2012.
Results
Patient characteristics
A total of 18,850 patients were prescribed AIT for grass
pollen allergy during the study period. Patient character-
istics are summarized in Table 1. Age of patients was
consistent between AIT modalities, with a mean age of
12.1 years and 34.3 years in the paediatric and adult
populations, respectively. In the paediatric population
63 % of patients were male. 88 % of patients were pub-
licly insured. Five percent of patients had a record of a
grass-related AIT prescription prior to index.
The most common co-morbidities observed in AIT
patients at index were asthma (42 %), conjunctivitis
(22 %), atopic dermatitis (20 %), and sinusitis (16 %).<18 years of age (n = 6425) ≥18 years of age (n = 12,425)
12.1 ± 3.24 (12.0) 34.3 ± 11.78 (33.0)
12.0 ± 3.31 (12.0) 35.2 ± 12.15 (34.0)
11.1 ± 3.41 (11.0) 35.9 ± 11.97 (35.0)
12.2 ± 3.20 (12.0) 33.9 ± 11.61 (32.0)
63 % 48 %
61 % 48 %
65 % 46 %
64 % 48 %
5729 (89 %) 10,773 (87 %)
696 (11 %) 1652 (13 %)
351 (5 %) 606 (5 %)
4 (<1 %) 27 (1 %)
11 (3 %) 24 (4 %)
336 (7 %) 555 (6 %)
2967 (46 %) 4937 (40 %)
1709 (27 %) 2506 (20 %)
1634 (25 %) 2136 (17 %)
859 (13 %) 2095 (17 %)
5053 (79 %) 8350 (67 %)
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of other allergies and urticaria occurred in less than 15 %
of patients. The percentage of patients with a co-
morbidity was largely consistent across AIT modalities
(77 % SLIT-tablet, 81 % SLIT drop, 79 % SCIT). The ma-
jority (71 %) of patients had a record of concomitant ARC
medication.
Prescribing trends by AIT modality
SCIT was the primary modality prescribed throughout
the study period; however, there was a statistically sig-
nificant increase in the proportion of patients treated
with SLIT-tablets from 8 % in 2006/2007 to 29 % in
2011/2012 (p < 0.001, McNemar’s test) (Fig. 1). The in-
crease in SLIT-tablets between each prescribing year was
also statistically significant (p < 0.001, Chi-squared test
for trend). Following SLIT-tablet approval in the paediat-
ric population in 2008, its share of prescribing increased
from 9 % in 2008/09 to 26 % in 2011/12. The proportion
of patients prescribed SLIT-drops was marginal at 3–5 %
of total prescribing each year; given this low usage, the
results and discussion will focus on SCIT and SLIT–tab-
let modalities. Note: the sample of physicians increased
throughout the study period (see “Characteristics of AIT
prescribers” below), therefore the conclusion cannot be
drawn that the number of patients treated with AIT
increased.
Prescribing trends by allergy season
Initiation of SLIT-tablet and SCIT within each prescribing
year generally had two peaks: autumn and the January–
April period (Fig. 2). GRAZAX® had a clear annual peak
in September–November, while Oralair® had a peak in ini-
tiations from January to March of each prescribing year;
however, a second peak indicated a proportion of patientsFig. 1 First allergy immunotherapy prescription in each prescribing year, b
study period; however, there was a statistically significant increase in the p
to 29 % in 2011/2012 (p < 0.001, McNemar’s test). The proportion of patien
each year(27 % on average) initiated Oralair® from September to
November. SCIT prescriptions exhibited a biphasic trend,
with initial prescriptions peaking from September to
October and in January. In the analysis of total prescrip-
tions (not shown graphically) initial and total SCIT and
Oralair® prescriptions tracked each other closely. Total
GRAZAX® prescriptions oscillated throughout the year,
indicative of its indication for year-round treatment. Less
than 10 % of all patients initiated treatment in-season
(May–July).
Characteristics of AIT prescribers
AIT was prescribed by GPs, dermatologists, ENT-
specialists, pediatricians and pneumologists (Fig. 3). The
DA panel increased over the study period, with the
number of physicians prescribing AIT increasing from
239 (2005) to 648 (2012). ENT-specialists and dermatol-
ogists together accounted for 67 % of SCIT prescribing,
while ENT-specialists accounted for 46 % of SLIT-tablet
prescribing.
Over the study period 756 unique physicians pre-
scribed AIT to adult patients. These physicians treated a
mean (SD) of 16.4 (30.5) adult AIT patients each. ENT-
specialists were the largest prescribers of SLIT-tablets to
adults (48 % of SLIT-tablet prescriptions). SCIT was
predominantly prescribed by dermatologists and ENT-
specialists, representing 42 % and 37 % of SCIT pre-
scriptions, respectively. In 2012 ENT-specialists remained
the largest prescribers of SLIT-tablets (50 % of prescrip-
tions), while ENT-specialists and dermatologists together
accounted for 79 % of SCIT prescriptions.
A total of 617 unique physicians prescribed AIT to
paediatric patients over the study period. These physi-
cians treated a mean (SD) of 10.4 (16.3) paediatric AIT
patients each. The largest prescribers of SLIT-tablet werey modality. SCIT was the primary modality prescribed throughout the
roportion of patients treated with SLIT-tablets from 8 % in 2006/2007
ts prescribed SLIT-drops was marginal at 3–5 % of total prescribing
Fig. 2 Initiation of allergy immunotherapy, by prescribing season. Initiation of SLIT-tablet and SCIT within the prescribing year generally had two
peaks: autumn and the January–April period. GRAZAX® had a clear annual peak in September–November, while Oralair® had a peak in initiations
from January to March of each prescribing year; however, a second peak indicated a proportion of patients (27 % on average) initiated Oralair®
from September to November. SCIT prescriptions exhibited a biphasic trend, with initial prescriptions peaking from September to October and
in January
McDonell et al. Allergy, Asthma & Clinical Immunology  (2015) 11:19 Page 5 of 7ENT-specialists (43 % of SLIT-tablet prescriptions) while
the largest prescribers of SCIT were paediatricians
(39 %). In 2012 SLIT-tablets were prescribed largely by
ENT-specialists (50 %), while paediatricians accounted
for 43 % of SCIT prescriptions.
Discussion
Main findings
This retrospective cohort study of patients treated with
AIT for grass pollen-induced AR in Germany uniquelyFig. 3 Allergy immunotherapy prescribing for total population, by
modality and physician specialty. AIT was prescribed by GPs,
dermatologists, ENT-specialists, pediatricians and pneumologists.
ENT-specialists and dermatologists together accounted for 67 % of
SCIT prescribing, while ENT-specialists accounted for 46 % of
SLIT-tablet prescribingexamined timing of initiation of treatment and prescrib-
ing trends over time. SCIT was the most commonly
prescribed AIT modality, although the proportion of pa-
tients receiving SLIT-tablet increased markedly following
launch in 2006. SLIT-drops had low utilization with a
share of 3–5 % of the total annual AIT prescribing across
the study period. Initiation of SLIT-tablets GRAZAX® and
Oralair® generally occurred in the autumn and January–
April period, respectively, with a large proportion of
Oralair® patients also receiving a prescription in au-
tumn. SCIT had a biphasic trend, with prescriptions
peaking in autumn and January. ENT-specialists and
dermatologists were the largest AIT prescribers overall.
The most common co-morbidities observed in patients
at index were asthma, conjunctivitis, atopic dermatitis,
and sinusitis.
Our findings in context
This is the first study of AIT prescribing trends in clin-
ical practice that examines all available treatment modal-
ities. Other studies have estimated the use of AIT among
AR patients or focused on a specific route of AIT.
Cross-sectional survey data and medical record review
of seasonal AR patients in a small German sample indi-
cated 35 % of children/adolescents and 65 % of adults
received AIT [23], while claims data from 2007 to 2010
in Germany found 7 % of patients with AR received AIT
[24]. A previous publication reported that approximately
25 % of AIT patients in Germany were treated with
SLIT-tablets or SLIT-drops [25], whereas our study
found that 33 % of patients received SLIT-tablets or
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[24] reported proportions of AR patients with co-morbid
asthma ranging from 16.0% to 17.4 % from 2007 to 2010
while asthma patients with co-morbid AR ranged from
47.3 to 48.1 %. The results of our study yielded estimates
of co-morbid asthma of 40 % in adult patients and 46 % in
paediatric patients prior to AIT initiation.
Clinical relevance
AIT is intended to induce immunologic tolerance hence
pre-seasonal initiation for grass pollen allergies is ideal
to minimize symptoms experienced during the season.
The decision of when to initiate AIT should therefore be
driven primarily by knowledge of timing of the grass
pollen season. There was evidence that a large propor-
tion of SLIT-tablet patients initiated treatment in the
February–April time period, rather than four months in
advance of the typical May-onset season as ideally rec-
ommended for optimal benefit. Furthermore, there was
evidence that Oralair®, a product recommended for use
only until the end of the season, is initiated in the
September–November period by an average of 27 % of
patients. While these patterns may reflect clinical experi-
ence surrounding the ability of patients to achieve ad-
equate benefit with a shorter lead time (e.g., 12 weeks
prior) or full treatment benefit with a greater lead time
(e.g., prior autumn season), these differences likely im-
pact the effectiveness and estimated cost of treatment.
The results also highlight insights on age of patients
receiving AIT and type of physicians prescribing each
modality. Given that AIT has been found to be well-
tolerated and effective in paediatric patients [16], it is in-
teresting that only one–third of patients in the study
sample were <18 years of age. This may indicate a need
for education on proven benefit of AIT in paediatric pa-
tients, particularly given evidence that initiation of AIT
in childhood may have additional benefits of preventing
the onset of new sensitizations and asthma [2–10].
In terms of prescribing physician trends it is likely that
physician preferences impact choice of modality. In the
paediatric population paediatricians were the largest pre-
scribers of SCIT, perhaps indicating a preference for this
more established modality; whereas in both adult and
paediatric patients ENT-specialists were the largest SLIT-
tablet prescribers, possibly as it is more convenient to ad-
minister. In markets where allergy specialists administer
AIT, the introduction of tablets may present greater com-
plexity due to the need to consider multiple treatment op-
tions and patient characteristics suited to a particular
modality. For other specialities, the oral SLIT-tablet may
be viewed as a simpler approach to administering AIT.
Furthermore, there may be economic incentives for SCIT
due to the need for visits for injection. While country-by-
country variation in reimbursement, available modalities,and specialty types may impact prescribing trends, our
findings can still be of interest to other markets, particu-
larly as different physician specialties determine how to
integrate new treatment modalities into their practice.Strengths & limitations
The primary strength of this study was the longitudinal
examination of AIT prescriptions written for manage-
ment of grass pollen-induced AR patients in clinical
practice for a large sample of patients. The study also
spanned the period pre- and post-SLIT-tablet launch,
providing insight on the impact of this new modality on
prescribing dynamics. Given the lack of other publica-
tions of real-world AIT usage, these findings contribute
to the body of evidence of AIT practice.
Limitations of this study were the inability to link pa-
tients between physicians, meaning a patient’s record in-
cluded only the treatment provided by a single physician,
and the reliance on physicians to accurately record infor-
mation within the electronic medical records. Results may
also have been impacted by the end of the German special
allergy budget which changed reimbursement for adminis-
tration of AIT during the study period.Conclusions
As the first analysis of AIT prescribing trends in grass
pollen-induced AR patients, this study highlighted the
differences in onset of treatment initiation for different
modalities and trends in prescribing by physician spe-
cialty. SCIT remained the dominant AIT modality in
Germany, despite strong uptake of SLIT-tablets. Initi-
ation of SCIT and Oralair® generally peaked in two sea-
sons while GRAZAX® prescriptions peaked in autumn.
ENT-specialists were the largest prescribers of SLIT-
tablets, while paediatricians, dermatologists, and ENT-
specialists were the largest SCIT prescribers. The study
spanned a period where the treatment paradigm adapted
to the introduction of the SLIT-tablet modality, with re-
sults showing predominance of particular modalities
within certain physician specialties likely based on differ-
ent treatment goals or needs. A possible reduction in the
onset of future sensitizations and asthma through in-
creased initiation of AIT in paediatric patients is an add-
itional benefit that warrants further consideration. While
the results are most relevant to clinical practice in
Germany, they may reflect patterns in other countries
with similar treatment paradigms.Abbreviations
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